Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report documented successful full hair regrowth in an 8-year-old with alopecia universalis after oral tofacitinib treatment, but mild headaches led to discontinuation.

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

This study analyzed teledermatology usage in mainland China during early 2020, finding that eczema, acne, and atopic dermatitis were the most common conditions treated and varied by age group.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

In this study, researchers developed a new photoactivatable Cre recombinase mouse model, DiLiCre, which allows precise light-induced genetic modifications and cell tracing, demonstrating its effectiveness for advancing biological and biomedical research.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

This review discusses the potential of bacterial extracellular vesicles in regenerative medicine, highlighting their advantages in addressing current EV challenges, and provides strategies for optimizing their preparation; it reports no new clinical results.

In this study, both physician and patient reports revealed that more severe alopecia areata was associated with higher emotional symptoms and greater activity limitations among patients.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

This article discusses the history and understanding of Tay syndrome, recognizing it as a distinct condition related to ichthyotic erythroderma, mental retardation, and brittle hair but reports no new clinical results.

This review explores the potential roles of extracellular vesicles in various medical fields, emphasizing their promise but noting the need for standardization and clinical testing before widespread application.

Milk-derived vesicles are promising for delivering drugs orally and treating various conditions.

New retinoids are effective for various skin conditions and are being developed to have fewer side effects.

This study found that specific genetic variations in the IRF2BP2 gene influence fleece structure in sheep, with one variant completely determining coat type and another significantly modifying fiber characteristics, providing valuable insights for improving fleece quality through selective breeding.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

This case report describes a patient with alopecia universalis who had an excellent and persistent response to oral tofacitinib treatment after one year.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

This study assessed oral tofacitinib's effectiveness and safety in treating different forms of alopecia, finding that 80% of patients experienced hair regrowth improvements over 24 weeks with no adverse events reported.

In this study, thread-embedding therapy enhanced hair regrowth in C57BL/6 mice by regulating growth factors associated with hair follicle anagen development and promoting cellular proliferation in hair follicles.

This study found that elevated TSPEAR expression in colorectal cancer was associated with poor overall prognosis and correlated with tumor infiltrating immune cells, suggesting its potential as a predictive biomarker.

This study found that iron deficiency anemia is a key factor in the development of telogen effluvium, and higher 25-hydroxyvitamin D3 levels in TE patients may be linked to increased UV exposure.

This study found that the "Trivedi Effect®" Biofield Energy Healing Treatment enhanced hair growth and melanogenesis in treated mice compared to untreated controls.

This study found that teledermatology significantly reduced wait times and increased appointment availability for uninsured Latino immigrants, effectively triaging 70% of cases without in-person visits.

This study concluded that overexpressing TERT and BMI1 in cultured human dermal papilla cells extended their lifespan and enhanced their ability to induce hair growth in mice.

This study observed that multiple familial trichoepitheliomas commonly presented with a cribriform histopathological tumor pattern, differentiating them from solitary trichoepitheliomas.

This research discusses potential cancer vaccine strategies using cell-based and DNA vector-based approaches, and suggests targeting the v3 splice variant of thioredoxin reductase 1 to inhibit cancer cell motility and metastasis formation.

This study found that nobiletin-loaded vesicles effectively restored skin condition in a mouse model of skin cancer, suggesting they are a promising treatment delivery system.

This study found that patients with telogen effluvium had slightly lower vitamin D levels compared to healthy controls, but the difference was not statistically significant.